Table 1

Correlations between LFA-REAL ClinRO and SLE disease activity measures, LFA-REAL PRO and other PRO measures, PGA with SLEDAI and BILAG at baseline, 24 and 52 weeks

A	LFA-REAL ClinRO			B	LFA-REAL PRO			C	PGA
A	Baseline	Week 24	Week 52	B	Baseline	Week 24	Week 52	C	Baseline	Week 24	Week 52
PGA	0.39	0.65	0.74	FACIT-F	−0.60	−0.55	−0.58	BILAG	0.17	0.51	0.57
BILAG	0.43	0.67	0.73	Lupus QoL	−0.42	−0.47	−0.46	SLEDAI-2K	0.09	0.45	0.52
SLEDAI-2K	0.35	0.60	0.62	SF-36v2 vitality	−0.40	−0.43	−0.58
				SF-36 PCS	−0.45	−0.53	−0.53

Correlation scale: very weak: 0–0.2; weak: 0.2–0.4; moderate: 0.4–0.6; strong: 0.6–0.8; very strong: 0.8–1.0. P<0.001 across all correlation analyses.
(A) Correlations between LFA-REAL ClinRO Total Score and SLE disease activity measures. LFA-REAL ClinRO; LFA-REAL PRO; SLEDAI-2K; BILAG; PGA.
(B) Correlations between LFA-REAL PRO Total Score and PRO measures. LFA-REAL PRO; SF-36; SF-36 PCS; Lupus QoL; FACIT-F. The LFA-REAL PRO increases with disease severity while the other PROs increase with improvement, accounting for the inverse correlations observed.
(C) Correlations between PGA and SLEDAI and BILAG.
BILAG, British Isles Lupus Assessment Group 2004 Index Total Score; ClinRO, clinician-reported outcome; FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue Scale; LFA-REAL, Lupus Foundation of America Rapid Evaluation of Activity in Lupus; Lupus QoL, Lupus Quality of Life questionnaire; PGA, Physician Global Assessment; PRO, patient-reported outcome; SF-36, 36-item Short-Form Health Survey; SF-36 PCS, 36-item SF-36 Physical Component Summary; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.